Bio View

Bio View Forward P/E

Forward P/E-forhold for Bio View (BIOV.TA) pr. 21. okt. 2026 er -1,54. I foregående år var Forward P/E-forhold -7,51 — en ændring på -79,47 % (højere).

Forward P/E

-1,54

YoY

-79,47%

Senest opdateret:

Forward P/E-forhold for Bio View er 2025 -1,54 . Forward P/E-forhold for Bio View var 2024 -7,51 . Det falder dermed med -79,47% højere sammenlignet med året før.

Bio View Forward P/E historik

  • 3 år

  • 10 år

  • 25 år

  • Maks

Forward P/E
Dato
Forward P/E
1. jan. 2018
-12,74 ILS
1. jan. 2019
9,36 ILS
1. jan. 2020
26,73 ILS
1. jan. 2021
10,82 ILS
1. jan. 2022
40,25 ILS
1. jan. 2023
61,69 ILS
1. jan. 2024
-7,51 ILS
1. jan. 2025
-1,54 ILS
Bio View Forward P/E historik
ÅRForward P/EYoY
-1,54-79,47%
-7,51-112,17%
61,69+53,26%
40,25+272,06%
10,82-59,52%
26,73+185,63%
9,36-173,43%
-12,74-32,47%
-18,87-454,39%
5,33-8,36%
5,81-48,16%
11,21—

Hent disse data via Eulerpool API

100.000 requests/md. gratis · intet kreditkort

Bio View Aktieanalyse

Hvad laver Bio View? BioView Ltd. generates revenue through the sale and servicing of its Duet automated cell diagnostic system, designed for use in cytology, cytogenetic, hematology, and pathology laboratories. The Duet system enables automated detection, classification, analysis, and counting of cells, offering unique capabilities in analyzing both cell morphology and genetic content simultaneously. Additional products include the ALLEGRO workstation for automated scanning of FISH probes without Brightfield scanning and the ACCORD workstation for semi-automated imaging of FISH in breast cancer (Her-2/Neu) analysis and FISH on tissue. These systems target medical professionals in cancer diagnosis, minimal-residual disease monitoring, prenatal and postnatal cytogenetic analyses, sperm cell studies, and rare-cell detection. The company's primary customers are laboratories specializing in cytology, cytogenetics, hematology, and pathology, including those focused on cancer diagnostics and genetic analysis. These institutions purchase the Duet system for routine diagnostic workflows and the ALLEGRO and ACCORD workstations for specialized applications such as FISH analysis in breast cancer and genetic studies. BioView Ltd. also provides ongoing servicing and support for its systems, contributing to recurring revenue streams. BioView Ltd. markets its products under the brand names Duet, ALLEGRO, and ACCORD, with the Duet system serving as the core offering for general cell analysis. The ALLEGRO and ACCORD workstations cater to niche applications in FISH-based diagnostics, particularly in oncology and genetic testing. The company's revenue is derived from direct sales of these systems to healthcare facilities and laboratories, with no mention of third-party partnerships or additional revenue streams beyond product sales and servicing. Bio View er et af de mest populære virksomheder på Eulerpool.com.

Hyppigt stillede spørgsmål om Bio View aktie

Forward P/E-forhold for Bio View er -1,54 i 2025.

Forward P/E-forhold for Bio View ændrede sig fra -7,51 til -1,54, hvilket repræsenterer en ændring på -79,47 %. Værdien er højere end i foregående år.

På Eulerpool kan du finde den fuldstændige historiske udvikling af Forward P/E-forhold Bio View siden 2006 – med årlige værdier, diagrammer og detaljeret analyse.

Forward P/E bruger estimeret fremtidig indtjening til at værdiansætte en aktie. Et lavere forward P/E i forhold til bagudrettet P/E tyder på, at analytikere forventer vækst i indtjeningen.

For at evaluere Forward P/E-forholds er det afgørende at sammenligne det med andre virksomheder i samme branche og sektor. På Eulerpool kan du finde branchsammenligninger for Forward P/E-forhold.

En 'god' varierer efter branche og virksomhedens udviklingsstadium. På Eulerpool kan du sammenligne Forward P/E-forholds Bio View med konkurrenter og branchegjennemsnittet for at afgøre, om den er attraktiv.

Hent disse data via Eulerpool API

100.000 requests/md. gratis · intet kreditkort

Værdiansættelse — Bio View

Alle nøgletal — Bio View